Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) News

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): $2.53

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ENZ News Items

ENZ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ENZ News From Around the Web

Below are the latest news stories about Enzo Biochem Inc that investors may wish to consider to help them evaluate ENZ as an investment opportunity.

Enzo Biochem (NYSE:ENZ) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Yahoo | January 22, 2022

Enzo Biochem issues notice of termination for CEO Elazar Rabbani

Enzo Biochem (ENZ) announced that on Jan. 21 the company served a notice of termination to former CEO Elazar Rabbani regarding his employment

Seeking Alpha | January 21, 2022

Evermore Global Advisors, LLC Buys Eneti Inc, Sells Enzo Biochem Inc, Calumet Specialty ...

Investment company Evermore Global Advisors, LLC (Current Portfolio) buys Eneti Inc, sells Enzo Biochem Inc, Calumet Specialty Products Partners LP, Vimeo Inc, Constellium SE during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Evermore Global Advisors, LLC.

Yahoo | January 20, 2022

Corrado Advisors, Llc Buys Innovator Emerging Markets Power Buffer ETF - Octo, Innovator ...

Investment company Corrado Advisors, Llc (Current Portfolio) buys Innovator Emerging Markets Power Buffer ETF - Octo, Innovator International Developed Power Buffer ETF, iShares Core S&P Total U.S.

Yahoo | January 14, 2022

Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors

NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors (the “Board”), effective immediately. The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members. Dr. Mary Tagliaferri will

Yahoo | January 3, 2022

Genetron (NASDAQ:GTH) and Enzo Biochem (NYSE:ENZ) Head-To-Head Survey

Genetron (NASDAQ:GTH) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Profitability This table compares Genetron and Enzo Biochems net margins, return on equity and return on []

Dakota Financial News | December 16, 2021

Enzo Biochem reports Q1 results

No summary available.

Seeking Alpha | December 15, 2021

Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update

Conference call and live webcast scheduled for today, Wednesday, December 15, 2021 at 4:30 pm (ET)

Intrado Digital Media | December 15, 2021

Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update

1Q FY 2022 revenues of $26.5 million vs. $24.8 million in 4Q FY 2021, representing a 7% sequential increaseCompany appoints Hamid Erfanian as Chief Executive Officer Consolidated manufacturing footprint at state-of-the-art Farmingdale, NY campus to enhance operational efficiencies Conference call and live webcast scheduled for today,Wednesday, December 15, 2021 at 4:30 pm (ET) NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company

Yahoo | December 15, 2021

Millennium Management LLC Raises Holdings in Enzo Biochem, Inc. (NYSE:ENZ)

Millennium Management LLC grew its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 324.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 414,682 shares of the medical research companys stock after purchasing an additional 316,940 shares during the period. Millennium []

Transcript Daily | December 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5862 seconds.